Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Epigral Limited Earnings Release 2023

Jan 19, 2023

59342_rns_2023-01-19_134d1a97-4285-47e0-8412-bf78489435ca.pdf

Earnings Release

Open in viewer

Opens in your device viewer

==> picture [511 x 84] intentionally omitted <==

19.01.2023

To,

National Stock Exchange of India Limited BSE Limited “Exchange Plaza”, Floor- 25, P J Tower, Bandra-Kurla Complex, Dalal Street, Bandra (East) Mumbai 400 051 Mumbai 400 001 SCRIP CODE: MFL SCRIP CODE: 543332

Dear Sir/s

Sub:- Q3 FY23 Press Release

With reference to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Q3 FY23 Press Release.

This is for information and records.

Yours faithfully,

For Meghmani Finechem Limited

KAMLESH Digitally signed by KAMLESH DINKARRA DINKARRAY MEHTA Date: 2023.01.19 Y MEHTA 13:52:38 +05'30'

K. D. Mehta Company Secretary & Compliance Officer Mem. No. FCS 2051

==> picture [82 x 58] intentionally omitted <==

Press Release

Meghmani Finechem’s Revenue up 27% in Q3FY23 CPVC resin capacity will be expanded by 1.5 times to 75,000 TPA

Jan 19, 2023: Meghmani Finechem Limited (MFL), India’s leading integrated chemical manufacturer, today announced its financial results for the quarter and nine-months ended December 31st, 2022. The company delivered a strong operating and financial performance. The chemical major posted a 27% jump in its revenue for Q3FY23 to 538 Cr as compared to Q3 of FY22.

Highlights: YoY comparison

Highlights: YoY comparison ₹ Cr
Particular Q3FY23 Q3FY22 Growth 9MFY23 9MFY22 Growth
Revenue from operations 422 538 27% 1,052 1,626 55%
EBITDA 141 167 18% 334 534 60%
PAT 70 77 11% 154 277 80%

Commenting on the results Mr Maulik Patel; Chairman and Managing Director – MFL said: “We have witnessed 18% volume growth in Q3FY23 resulting in YoY revenue growth of 27%. Even in this volatile market, we have seen volume growth in all our products and have also grown on absolute basis. The new products that we commissioned in 9MFY23 have started contributing to P&L and we expect that contribution to enhance from Q4FY23 onwards. Revenue contribution from Derivatives & Specialty segment increased to 31% in Q3FY23 vs 25% in Q3FY22.

For CPVC resin, our product is well accepted by all customers and we are expected to reach optimum capacity utilization in Q4FY23. Considering the market size and growth potential, we are increasing our CPVC resin capacity to 75,000 TPA, by adding another 45,000 TPA. As we are ready with basic infra requirement for CPVC resin expansion, we will be able to do this project faster and lower capex compared to our first project. This expansion will further strengthen our integrated complex as Chlorine will be consumed as one of the raw materials in CPVC resin.

MFL board has declared its 1st maiden interim dividend of 25% on face value of ₹ 10 (₹ 2.5 per equity share). With our expansion plans, we are moving in line with our long-term vision to become a fully integrated facility company catering to diversified industries and consistent growth.”

The key performance highlights are:

Strategic Update for 9MFY2023:

  • MFL is expanding its CPVC Resin capacity to 75,000 TPA by adding further 45,000 TPA. The project is expected to get commissioned by Q4FY24

  • MFL board has declared its 1[st] maiden interim dividend of 25% on face value of ₹ 10 (₹ 2.5 per equity share)

  • In 9MFY23, MFL commissioned Epichlorohydrin on 1[st] June, CPVC on 18[th] July and additional capacity of Caustic Soda on 30[th] September. All 3 projects were completed within committed timelines and within capex limit. These projects will contribute volume partially in FY23 and fully in FY24

  • Expansion projects of Chlorotoluene & its value chain and R&D Centre is moving as per schedule

  • MFL acquired 2,89,844.41 sq. m. land in Dahej (close to current complex) for future growth plans

  • MFL entered in JV to set up 18.34 MW Hybrid Power Plant to meet energy requirement at the plant

Q3FY23 Operational Highlights (YoY):

  • Volume grew from all the products in Q3FY23 led to 18% volume growth on YoY basis

  • Caustic Soda & Caustic Potash ECU realization was up 2% & 40% respectively

  • CMS sales realization was down 33% and H2O2 sales realization was up 9%

Q3FY2023 Financial Highlights (YoY):

  • Revenue grew 27% to ₹ 538 Cr on account of volume growth and higher realizations from majority products. Revenue contribution from Derivative & Specialty segment increased to 31% in Q3FY23 vs 25% in Q3FY22

  • EBITDA grew 18% YoY. Margin continuous to be strong at 31%, though slightly lower on account of high cost raw material compared to realization

  • PAT increased 11% YoY to ₹ 77 Cr

9MFY2023 Financial Highlights (YoY):

  • 9MFY23 Revenue, EBIDTA and PAT has crossed FY22’s full year numbers

  • Revenue grew 55% to ₹ 1,626 Cr on account of 7% volume growth and high realizations

  • PAT grew 80% to ₹ 277 Cr and margin improved to 17% on account of higher realizations vs 15% in 9MFY22

  • ROCE and ROE improved to 35% and 46% respectively on account of higher realization and volume growth

About Meghmani Finechem Limited

Meghmani Finechem Limited (“MFL”), incorporated in 2007, is a leading integrated manufacturer of chemicals in India. The company has state of the art manufacturing facilities in Gujarat, Dahej – a leading PCPIR region in the country. MFL’s Dahej facility is a backward and forward integrated and automated complex with a well-established infrastructure and Captive Power Plants. The company is India’s 4th largest manufacturer of Caustic Soda, Chlorine and Hydrogen and a leading manufacturer of Caustic Potash, Chloromethanes and Hydrogen Peroxide. MFL is the 1st to set up an Epichlorohydrin plant and largest capacity plant of CPVC resin, in India.

MFL is further expanding into Chlorotoluene & its value chain to strengthen its position in the Specialty Chemical segment and expanding capacity in CPVC resin to 75 KTPA. The company is focused on sustainable value creation for all its stakeholders and has been awarded with the Responsible Care certificate.